Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.

Oncology reports - 1 Sept 2004

Harada Mamoru, Matsueda Satoko, Yao Akihisa, Ogata Rika, Noguchi Masanori, Itoh Kyogo

Abstract excerpt

Prostate-related antigens, including prostate-specific membrane antigen (PSMA) and prostatic acid phosphatase (PAP), can be targets in specific immunotherapy for prostate cancer. In this study, we attempted to newly identify epitope peptides from these 2 antigens, which are immunogenic in human histocompatibility leukocyte antigen (HLA)-A2+ prostate cancer patients. Twenty-nine peptides (PSMA with 15 and PAP with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Surface
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Epitopes

Share to HLA-A2 Antigen

Share to Immunoglobulin G

Share to Immunotherapy

Share to Leukocytes, Mononuclear

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 15289844

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.PMID 15289844Read ↗

An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.Semantic proximity Read ↗

Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles.Semantic proximity Read ↗

Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.Semantic proximity Read ↗

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigenSemantic proximity Read ↗

Identification of HLA-DRB1*1501-restricted T-cell epitopes from human prostatic acid phosphatase.Semantic proximity Read ↗

Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate CancerSemantic proximity Read ↗

Relationship between HLA-DR antigen and HLA-DRB1 alleles and prostate cancer in Japanese men.Semantic proximity Read ↗

Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer.Semantic proximity Read ↗

Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation.Semantic proximity Read ↗

Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.Semantic proximity Read ↗

Evaluation of Phage Display Discovered Peptides as Ligands for Prostate-Specific Membrane Antigen (PSMA)Semantic proximity Read ↗

Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.